IPHA
Innate Pharma S.A. NASDAQ Listed Oct 17, 2019$1.89
Mkt Cap $177.5M
52w Low $1.17
49.3% of range
52w High $2.63
50d MA $1.67
200d MA $1.76
P/E (TTM)
—
EV/EBITDA
—
P/B
—
Debt/Equity
-1.0x
ROE
—
P/FCF
-3.2x
RSI (14)
53.80
ATR (14)
$0.08
Beta
0.74
50d MA
$1.67
200d MA
$1.76
Avg Volume
124.0K
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
117, Avenue de Luminy · Marseille 13009 · FR
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 13, 2026 | BMO | -0.35 | -0.35 | +0.8% | 1.36 | +0.7% | -2.9% | +64.4% | -6.9% | +11.4% | -9.8% | — |
| Sep 17, 2025 | BMO | -0.14 | -0.29 | -106.5% | 2.05 | -2.9% | -5.4% | -3.6% | -2.1% | -1.6% | +2.2% | — |
| May 12, 2025 | BMO | -0.27 | -0.32 | -18.3% | 2.32 | +0.0% | -12.1% | +2.0% | +1.4% | +0.0% | -1.4% | — |
| Nov 17, 2020 | BMO | -0.34 | -0.15 | +56.1% | 4.59 | +4.1% | +4.4% | +4.8% | +1.4% | -3.7% | +2.4% | — |
| May 12, 2020 | BMO | -0.43 | -0.59 | -36.6% | 8.20 | -10.9% | -6.5% | -8.9% | -4.1% | -2.4% | +3.4% | — |
| Nov 13, 2019 | BMO | — | 0.23 | — | 6.48 | -0.6% | -3.1% | -3.7% | -0.3% | -4.5% | +9.2% | — |
| May 15, 2019 | BMO | — | 0.36 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2018 | BMO | — | -0.30 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2017 | BMO | — | -0.54 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2017 | BMO | — | -0.49 | — | — | — | — | — | — | — | — | — |
| Dec 31, 2016 | BMO | — | 0.30 | — | — | — | — | — | — | — | — | — |
| Jun 30, 2016 | BMO | — | -0.07 | — | — | — | — | — | — | — | — | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.39 | $1.36 | -2.2% | -2.9% | +7.4% | +0.0% | -2.8% | +2.1% |
| Oct 29 | BTIG | Maintains | Buy → Buy | — | $2.09 | $2.08 | -0.5% | -1.0% | -3.9% | -1.0% | -3.6% | -3.2% |
| Oct 29 | HC Wainwright & Co. | Upgrade | Neutral → Buy | — | $2.09 | $2.08 | -0.5% | -1.0% | -3.9% | -1.0% | -3.6% | -3.2% |
| Sep 18 | Leerink Partners | Downgrade | Outperform → Market Perform | — | $2.05 | $1.99 | -2.9% | -5.4% | -3.6% | -2.1% | -1.6% | +2.2% |
| Sep 18 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $2.05 | $1.99 | -2.9% | -5.4% | -3.6% | -2.1% | -1.6% | +2.2% |
| Apr 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.00 | $2.00 | +0.0% | +0.5% | -1.5% | +5.6% | +5.3% | +1.4% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $2.03 | +3.0% | +0.5% | -10.1% | +7.3% | -6.3% | +7.3% |
| Feb 6 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.95 | $2.01 | +3.1% | +2.6% | -5.0% | +1.1% | +0.0% | -1.0% |
| Jan 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.73 | +3.6% | +1.2% | +4.7% | +0.0% | -5.6% | +6.0% |
| Dec 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.47 | $1.84 | +25.2% | +29.3% | -5.3% | -6.1% | -8.3% | +94.8% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.67 | $1.60 | -4.2% | -13.8% | +6.3% | -2.6% | +13.4% | +0.6% |
| Nov 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.85 | $1.75 | -5.4% | +2.7% | -11.6% | -0.6% | -13.8% | +6.2% |
| Sep 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.28 | $2.28 | +0.0% | -0.9% | -4.0% | +1.8% | +1.8% | +0.0% |
| Jun 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.55 | $2.53 | -0.8% | -2.7% | -4.4% | -0.8% | -10.6% | -3.8% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.64 | $2.61 | -1.1% | -4.9% | +2.4% | +5.4% | +5.2% | +1.8% |
| Apr 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.52 | $2.53 | +0.4% | -1.6% | +0.0% | -2.4% | +7.0% | -6.9% |
| Mar 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.41 | $2.36 | -2.1% | -1.7% | +1.3% | +1.7% | -2.5% | +21.0% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.58 | $2.41 | -6.6% | -4.7% | -3.7% | +3.4% | +2.4% | -3.2% |
| Sep 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.97 | $2.85 | -4.0% | -7.4% | -2.7% | +5.0% | -4.6% | -0.4% |
| Jun 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.26 | $3.32 | +1.8% | +6.7% | -8.3% | +6.9% | -0.9% | -6.2% |
| Mar 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.67 | $2.82 | +5.6% | +7.9% | +5.6% | -6.1% | -1.6% | +5.4% |
| Nov 15 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.48 | $2.28 | -8.1% | -5.6% | -3.4% | -2.2% | +1.4% | -1.8% |
| Sep 16 | Citigroup | Maintains | Buy → Buy | — | $2.54 | $2.47 | -2.8% | +20.9% | -15.6% | -6.2% | +1.6% | +0.0% |
| Aug 2 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.81 | $2.68 | -4.6% | -3.7% | +1.7% | +0.7% | -0.4% | +0.0% |
| May 11 | SVB Leerink | Maintains | Outperform → Outperform | — | $2.71 | $2.86 | +5.3% | +3.9% | -1.1% | +2.9% | +4.4% | +2.4% |
| Sep 17 | SVB Leerink | Maintains | Outperform → Outperform | — | $5.75 | $7.60 | +32.2% | +40.9% | -0.6% | -7.0% | -3.9% | -2.8% |
| Sep 3 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $4.18 | $4.48 | +7.2% | +47.1% | -5.2% | +2.4% | +4.7% | -3.7% |
| Sep 2 | SVB Leerink | Upgrade | Market Perform → Outperform | — | $3.62 | $5.23 | +44.5% | +15.5% | +47.1% | -5.2% | +2.4% | +4.7% |
| Mar 19 | SVB Leerink | Maintains | Market Perform → Market Perform | — | $4.45 | $4.33 | -2.7% | +1.1% | +2.9% | -3.9% | -3.6% | +4.0% |
| Dec 15 | SVB Leerink | Downgrade | Outperform → Market Perform | — | $4.39 | $4.31 | -1.8% | -2.7% | -4.6% | +2.3% | +3.4% | -1.2% |
| Dec 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.36 | $4.28 | -1.8% | +0.7% | -2.7% | -4.6% | +2.3% | +3.4% |
| Nov 24 | Goldman Sachs | Maintains | Neutral → Neutral | — | $5.02 | $5.30 | +5.6% | +2.8% | +0.4% | +7.3% | -4.0% | +3.0% |
| Sep 9 | SVB Leerink | Maintains | Outperform → Outperform | — | $4.45 | $4.45 | -0.0% | -8.1% | -4.8% | +0.7% | +11.5% | -0.5% |
| May 14 | SVB Leerink | Maintains | Outperform → Outperform | — | $6.99 | $6.68 | -4.4% | -4.1% | -2.4% | +3.4% | -5.5% | +0.3% |
No insider trades available.
No recent filings available.
Institutional (13F) — Top 7
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 92,788 | $162K | Reduced | Dec 2025 |
| 2 | Jane Street Group, Llc | 92,753 | $162K | New | Dec 2025 |
| 3 | Lion Point Capital, Lp | 81,151 | $104K | — | Mar 2026 |
| 4 | Millennium Management | 10,064 | $13K | Reduced | Mar 2026 |
| 5 | Ubs Group Ag | 861 | $1K | Reduced | Mar 2026 |
| 6 | Gamma Investing Llc | 240 | $307 | Reduced | Mar 2026 |
| 7 | Farther Finance Advisors, Llc | 10 | $14 | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 0
All ↗
No N-PORT holders found.
Valuation
Market Cap
$177.5M
Enterprise Value
$141.3M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.21x
P/B
—
P/S
10.97x
P/FCF
-3.19x
EV/EBITDA
—
Shares Out
89.4M
Financials (TTM)
Revenue
$15.4M
Net Income
-$98.4M
EBITDA
-$102.7M
Free Cash Flow
-$50.8M
Op Cash Flow
-$50.7M
EPS Basic
$-0.53
EPS Diluted
$-1.16
EPS Forward
$-0.26
Gross Margin
100.0%
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$62.7M
Total Liab.
$84.4M
Total Equity
-$21.7M
Cash
$34.3M
LT Debt
$13.8M
Book Value/Sh
$-0.24
Debt/Equity
-1.04x
Current Ratio
1.27
Quick Ratio
1.27
Returns & Growth
ROE
—
ROA
—
ROIC
-134.7%
Rev Growth YoY
-77.9%
EPS Growth YoY
+13.1%
Price Returns
2W
-15.7%
1M
+27.1%
3M
+6.4%
6M
-6.2%
12M
-16.4%
Technicals
52W High
$2.63
52W Low
$1.17
50d MA
$1.67
200d MA
$1.76
RSI (14)
53.80
ATR (14)
$0.08
Beta
0.74
Avg Volume
124K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.50
High
$5.00
Low
$2.00
Median
$3.50
Data updated apr 26, 2026 11:03am
· Source: financialmodelingprep.com